









市场行情
/
股票
/
nasdaq-rgen
/

Repligen Corp

RGEN

160.646USD

+3.256+2.07%

交易中（美东）报价延迟15分钟

9.04B总市值

5757.92市盈率 TTM



Repligen Corp

160.646

+3.256+2.07%

概览公司财务分析

概览

公司

财务

分析

关于 Repligen Corp 公司

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Repligen Corp简介



公司代码RGEN

公司名称Repligen Corp

上市日期Apr 29, 1986

CEOLoeillot (Olivier)

员工数量1778

证券类型Ordinary Share

年结日Apr 29

公司地址Building 1, Suite 100

城市WALTHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02453

电话17814499560

网址https://www.repligen.com/

公司代码RGEN

上市日期Apr 29, 1986

CEOLoeillot (Olivier)

Repligen Corp公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-53.90%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

Mr. Jason K. Garland

Chief Financial Officer

Mr. Tony John Hunt

Executive Chairman of the Board

Dr. Martin D. Madaus, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Ms. Karen A. Dawes

Lead Independent Director

91.29K

+1.08%

Mr. Glenn P. Muir

Independent Director

32.55K

+3.08%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+147.18%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-53.90%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+24.53%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+41.49%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

North America

89.36M

49.00%

Europe

69.30M

38.00%

APAC/Other

23.71M

13.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月8日周一

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

8.94%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

其他

65.91%

持股股东

占比

The Vanguard Group, Inc.

8.94%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

其他

65.91%

股东类型

持股股东

占比

Investment Advisor

59.79%

Investment Advisor/Hedge Fund

29.04%

Hedge Fund

15.73%

Individual Investor

6.33%

Research Firm

2.20%

Pension Fund

2.00%

Bank and Trust

0.71%

Sovereign Wealth Fund

0.60%

Family Office

0.50%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1027

55.23M

98.12%

-6.26M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

2023Q2

1050

59.01M

105.99%

+1.34M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

5.07M

-2.87K

-0.06%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.71M

8.37%

-180.36K

-3.69%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.43M

6.1%

-3.13M

-47.69%

Aug 31, 2025

Roy T. Eddleman UEO

3.31M

5.89%

-67.50K

-2.00%

Dec 31, 2024

Fidelity Management & Research Company LLC

1.36M

2.43%

+842.96K

+161.67%

Jun 30, 2025

State Street Investment Management (US)

1.62M

2.88%

-66.31K

-3.93%

Jun 30, 2025

Citadel Advisors LLC

1.06M

1.89%

-266.68K

-20.06%

Jun 30, 2025

Point72 Asset Management, L.P.

1.91M

3.4%

+796.75K

+71.36%

Jun 30, 2025

Holocene Advisors, LP

936.81K

1.67%

-23.17K

-2.41%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

First Trust NYSE Arca Biotechnology Index Fund

3.45%

Alger Mid Cap 40 ETF

3.1%

Congress SMid Growth ETF

2.46%

iShares Health Innovation Active ETF

2.28%

VanEck Biotech ETF

1.34%

Franklin Genomic Advancements ETF

1.23%

Pacer US Export Leaders ETF

1.18%

Alger 35 ETF

1.15%

WisdomTree BioRevolution Fund

1.06%

iShares Biotechnology ETF

0.7%

First Trust NYSE Arca Biotechnology Index Fund

占比3.45%

Alger Mid Cap 40 ETF

占比3.1%

Congress SMid Growth ETF

占比2.46%

iShares Health Innovation Active ETF

占比2.28%

VanEck Biotech ETF

占比1.34%

Franklin Genomic Advancements ETF

占比1.23%

Pacer US Export Leaders ETF

占比1.18%

Alger 35 ETF

占比1.15%

WisdomTree BioRevolution Fund

占比1.06%

iShares Biotechnology ETF

占比0.7%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Repligen Corp的前五大股东是谁？



Repligen Corp 的前五大股东如下：
The Vanguard Group, Inc.持有股份：5.07M，占总股份比例：9.00%。
BlackRock Institutional Trust Company, N.A.持有股份：4.71M，占总股份比例：8.37%。
T. Rowe Price Associates, Inc.持有股份：3.43M，占总股份比例：6.10%。
Roy T. Eddleman UEO持有股份：3.31M，占总股份比例：5.89%。
Fidelity Management & Research Company LLC持有股份：1.36M，占总股份比例：2.43%。